CA-GUPSHUP
23.9.2021 12:02:07 CEST | Business Wire | Press release
Gupshup, the leader in conversational messaging, today announced that it has acquired New Jersey based Dotgo. Dotgo is the global industry leader in RCS business messaging (RBM), with award-winning technologies such as the RichOTP® , RichSMS™, Bot Store® , and MaaP (Messaging as a Platform) that foster the growth of RCS Business Messaging. A strong partner of Google, Mavenir, Synchronoss, Vodafone, and Orange, Dotgo manages RBM in several markets, and operates the world’s largest RBM Hub with global connectivity to RCS users across the world. Dotgo is uniquely positioned to help brands integrate, with simple APIs, the RCS channel into their customer communications, whether for sales, support, services, or other business processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005293/en/
Dotgo, powered by a founding team with a rich history of tech innovation, is a Cohort 6 graduate of the IIT Startups accelerator. Dotgo grew rapidly in 2021 as RCS gained traction in North America, Europe, India, Brazil, and Nigeria. Dotgo’s MaaP, offered in partnership with, and pre-integrated with, Google Jibe platform, has been selected to operate RCS business messaging at several mobile operators. Dotgo has been a leading contributor at the Mobile Ecosystem Forum and GSMA in defining standards and processes for RCS business messaging.
Dotgo will significantly strengthen Gupshup’s conversational messaging platform that enables businesses and developers to build rich customer experiences. Gupshup also plans to leverage Dotgo’s strong experience and presence in Africa to expand there.
“Conversational experiences are becoming the key to business-customer interactions, and the RCS messaging channel is a critical enabler,” said Beerud Sheth, co-founder and CEO, Gupshup. “Dotgo’s product innovation, market traction, and thought leadership in the RCS ecosystem is truly impressive. Together, we’ll be able to offer a broader range of conversational messaging solutions to businesses and developers. We are excited to welcome them to the Gupshup family.”
Inderpal Singh Mumick, co-founder and CEO of Dotgo, said, “RCS business messaging is destined to change the way businesses communicate with their customers. We started Dotgo to create APIs that make it easy for brands and other players in the ecosystem to adopt RCS, while taking care of and hiding all the backend complexity from our customers. With the addition of RCS, Gupshup will undoubtedly be the strongest IP messaging company, and thus helps us accelerate our mission.”
Johanna Kollar, Partnerships Lead, Communication Products, Google, said, “We congratulate Dotgo and Gupshup on this acquisition. We have worked closely with Dotgo, and are very impressed by the quality of their products and services. We look forward to growing our relationship as the Dotgo team becomes a part of Gupshup.”
“The Dotgo team members were visionaries in recognizing the potential of RCS at a time when it had little adoption. We congratulate them on building industry leading products that are being adopted by customers across the world, just as RCS is taking off. Their bet proved prescient, and combining with an exceptional company like Gupshup will create a far stronger value proposition in the market,” said Naren Gupta, Managing Director, Nexus Venture Partners.
RCS will be a key messaging channel in Gupshup’s Conversational Messaging Platform, supplementing 30 other messaging channels available to customers via Gupshup’s Single API for messaging. RCS, a part of the 5G standard, is the next generation of SMS that includes pictures, audio, video, and presence, combined with enhanced security and encryption. RCS messages are delivered to native messaging apps such as Google Business Messages and Samsung Messages on Android phones. RCS Business Messaging uses the rich and interactive features of RCS to enable branded and secure business messaging. RCS is available globally with over 600M monthly active users, including about 20% of India’s smartphone users.
About Dotgo
Dotgo®, a global leader in RCS, is building the APIs and cloud platforms needed in a world where every business must have a presence inside messaging apps, just as they have web sites and smartphone apps. Dotgo’s APIs and services enable brands and developers to build conversational experiences that transform customer interactions, and help mobile operators to launch, manage, and monetize RCS business messaging. Dotgo is the provider of the Dotgo Bot Store ®, world’s first and largest directory of RCS and WhatsApp bots, Dotgo MaaP, RichOTP®, RichSMS™, and the RBM Hub. Dotgo is a Google partner, a WhatsApp Business Solution Provider, and a member of the Mobile Ecosystem Forum. For more information, visit www.dotgo.com . Bot Store, Dotgo, and RichOTP are registered trademarks of Dotgo Systems Inc. in USA and other jurisdictions.
About Gupshup
Gupshup enables better customer engagement through conversational messaging. Gupshup is the leading conversational messaging platform, powering over 6 billion messages per month. Across verticals, thousands of large and small businesses in emerging markets use Gupshup to build conversational experiences across marketing, sales and support. Gupshup's carrier-grade platform provides a single messaging API for 30+ channels, a rich conversational experience-building tool kit for any use case and a network of emerging market partnerships across messaging channels, device manufacturers, ISVs and operators. With Gupshup, businesses have made conversations an integral part of their customer engagement success. Gupshup is present in India, LATAM, South East Asia, Middle East, Eastern Europe, Africa and the United States. Visit www.gupshup.io . Converse with the Gupshup bot.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005293/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom